{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:31:31Z","timestamp":1770748291952,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":385,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.14283\/jpad.2023.72","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T08:18:43Z","timestamp":1685953123000},"page":"339-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinicians' Perspectives on How Disease Modifying Drugs for Alzheimer's Disease Impact Specialty Care"],"prefix":"10.1016","volume":"10","author":[{"given":"Serge","family":"Gauthier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.P.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rosa-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.14283\/jpad.2023.72_bib1","first-page":"398","article-title":"Aducanemab; Appropriate Use Recommendations","volume":"4","author":"Cummings","year":"2021","journal-title":"J Prev Alz Dis"},{"issue":"10","key":"10.14283\/jpad.2023.72_bib2","first-page":"362","article-title":"Lecanemab: Appropriate Use Recommendations","volume":"3","author":"Cummings","year":"2023","journal-title":"J Prev Alz Dis"},{"issue":"9","key":"10.14283\/jpad.2023.72_bib3","first-page":"197","article-title":"Two randomized Phase 3 studies of aducanumab in early Alzheimer's disease","volume":"2","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alz Dis"},{"key":"10.14283\/jpad.2023.72_bib4","article-title":"Lecanemab in early Alzheimer's disease","author":"Van Dyck","year":"2022","journal-title":"N Eng J Med"},{"key":"10.14283\/jpad.2023.72_bib5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Eng J Med"},{"key":"10.14283\/jpad.2023.72_bib6","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating Scale (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.14283\/jpad.2023.72_bib7","doi-asserted-by":"crossref","first-page":"o3010","DOI":"10.1136\/bmj.o3010","article-title":"Lecanemab for Alzheimer's disease","volume":"379","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"10.14283\/jpad.2023.72_bib8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","article-title":"Association of phosphorylated tau biomarkers with amyloid Positron Emission Tomography vs tau Positron Emission Tomography","volume":"80","author":"Therriault","year":"2023","journal-title":"JAMA Neurology"},{"issue":"10","key":"10.14283\/jpad.2023.72_bib9","first-page":"357","article-title":"Lecanemab: Appropriate Use Recommendations - a commentary from a European perspective","volume":"3","author":"Fr\u00f6lich","year":"2023","journal-title":"J Prev Alz Dis"},{"key":"10.14283\/jpad.2023.72_bib10","unstructured":"Gauthier S, Webster C, Servaes S, Morais JA, Rosa-Neto P. World Alzheimer Report 2022. Life after diagnosis: navigating treatment, care and support. London, England. Alzheimer's Disease International. Alzint.org."},{"key":"10.14283\/jpad.2023.72_bib11","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jalz.2019.09.075","article-title":"The paty forward in Alzheimer's disease therapeutics: reevaluating the amyloid cascade hypothesis","volume":"16","author":"Tolar","year":"2020","journal-title":"Alzheimer's Dement"},{"issue":"10","key":"10.14283\/jpad.2023.72_bib12","first-page":"378","article-title":"Clinical efficacy in individual patients treated with Lecanemab","volume":"3","author":"Gauthier","year":"2023","journal-title":"J Prev Alz Dis"},{"issue":"10","key":"10.14283\/jpad.2023.72_bib13","first-page":"595","article-title":"\u2018Time saved' as a demonstration of clinical meaningfulness and illustrated using the donanemab TRAILBLAZER-ALZ study findings","volume":"3","author":"Dickson","year":"2023","journal-title":"J Prev Alz Dis"},{"issue":"6","key":"10.14283\/jpad.2023.72_bib14","volume":"218","year":"2023","journal-title":"MJA"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724001857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724001857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:05:32Z","timestamp":1736467532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724001857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2274580724001857"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2023.72","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicians' Perspectives on How Disease Modifying Drugs for Alzheimer's Disease Impact Specialty Care","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2023.72","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}